Dan Teng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dan Teng has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Mingyue Zheng
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
4 shared publications - Xutong Li
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
4 shared publications Jingyi Meng
School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
2 shared publications- Sulin Zhang
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China
2 shared publications - Xiaomin Luo
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
2 shared publications - Xinyu Jiang
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation
Aberrant activation of the STING signaling pathway is involved with aging-related inflammation, yet no STING-targeting therapeutics are clinically approved. Here, we identify Omaveloxolone, an FDA-approved drug for Friedreich’s ataxia, as a potent STING degrader (DC 50 = 118 nM, D max = 98.6%) via high-throughput screening. Omaveloxolone binds non-covalently to the base of the STING ligand-binding domain (LBD) with high affinity ( K D = 21.4 nM) and exhibits crowbar-like behavior consistent with STING conformational destabilization: it hinders LBD closure, increases hydrophobic exposure, and reduces thermal stability. This conformational perturbation is proposed to enhance recognition by the E3 ubiquitin ligase HUWE1, leading to K27-linked ubiquitination at STING lysines K236/K347/K370 and proteasomal degradation. In vivo, Omaveloxolone depletes STING, suppresses downstream inflammatory signaling, and ameliorates aging-related inflammatory phenotypes in aged male mice. Because Omaveloxolone is also an established NRF2 activator, these in vivo benefits likely reflect dual modulation of inflammatory and antioxidant pathways. This study implicates Omaveloxolone as a molecular crowbar-like STING degrader and provides a mechanistic framework for targeting STING via conformational perturbation.
- 17 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessOmaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation
Aberrant activation of the STING signaling pathway is involved with aging-related inflammation, yet no STING-targeting therapeutics are clinically approved. Here, we identify Omaveloxolone, an FDA-approved drug for Friedreich’s ataxia, as a potent STING degrader (DC 50 = 118 nM, D max = 98.6%) via high-throughput screening. Omaveloxolone binds non-covalently to the base of the STING ligand-binding domain (LBD) with high affinity ( K D = 21.4 nM) and exhibits crowbar-like behavior consistent with STING conformational destabilization: it hinders LBD closure, increases hydrophobic exposure, and reduces thermal stability. This conformational perturbation is proposed to enhance recognition by the E3 ubiquitin ligase HUWE1, leading to K27-linked ubiquitination at STING lysines K236/K347/K370 and proteasomal degradation. In vivo, Omaveloxolone depletes STING, suppresses downstream inflammatory signaling, and ameliorates aging-related inflammatory phenotypes in aged male mice. Because Omaveloxolone is also an established NRF2 activator, these in vivo benefits likely reflect dual modulation of inflammatory and antioxidant pathways. This study implicates Omaveloxolone as a molecular crowbar-like STING degrader and provides a mechanistic framework for targeting STING via conformational perturbation.
- Open Access
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Deep residual learning for molecular force fields
Accurate descriptions of interactions between atoms are essential for molecular simulations used to study biology and support drug discovery. Existing force fields often face a trade-off between physical reliability, computational efficiency, and accuracy across unfamiliar molecules. Here we show that Residual Learning Force Field, a hybrid machine learning force field, can reduce this trade-off by combining simple physics-based descriptions of bonded interactions with learned corrections for remaining energetic effects. The two components are trained together through a three-step strategy so that each contributes complementary information. In tests covering drug-like molecules, molecular dimers, torsional energy profiles, energy-minimum structures, and biomolecular simulations, Residual Learning Force Field gives accurate and stable predictions across diverse systems. These results suggest that combining physical constraints with data-driven corrections can provide a practical route toward more reliable and efficient molecular simulation for biological research and drug discovery.
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDeep residual learning for molecular force fields
Accurate descriptions of interactions between atoms are essential for molecular simulations used to study biology and support drug discovery. Existing force fields often face a trade-off between physical reliability, computational efficiency, and accuracy across unfamiliar molecules. Here we show that Residual Learning Force Field, a hybrid machine learning force field, can reduce this trade-off by combining simple physics-based descriptions of bonded interactions with learned corrections for remaining energetic effects. The two components are trained together through a three-step strategy so that each contributes complementary information. In tests covering drug-like molecules, molecular dimers, torsional energy profiles, energy-minimum structures, and biomolecular simulations, Residual Learning Force Field gives accurate and stable predictions across diverse systems. These results suggest that combining physical constraints with data-driven corrections can provide a practical route toward more reliable and efficient molecular simulation for biological research and drug discovery.
- 13 December 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 168, 109363
Discovery of novel selective PRMT5-MTA inhibitors through structure-based virtual screening
- 13 December 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 168, 109363
Discovery of novel selective PRMT5-MTA inhibitors through structure-based virtual screening
- Open Access
- 22 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Deep Residual Learning for Molecular Force Fields
Accurate interatomic interaction modeling via force fields is critical for biological studies and drug discovery, but balancing accuracy and generalizability remains challenging. We introduce ResFF (Residual Learning Force Field), a hybrid machine learning force field that employs deep residual learning to integrate physics-based learnable molecular mechanics covalent terms with residual corrections from a lightweight equivariant neural network. Through a three-stage joint optimization, the two components are trained in a complementary manner to achieve optimal performance. Benchmarks show ResFF outperforms classical and neural network force fields in generalization (mean absolute error (MAE): 1.16 kcal/mol on Gen2-Opt, 0.90 kcal/mol on DES370K), torsional profiles (MAE: 0.45/0.48 kcal/mol on TorsionNet-500 and Torison Scan), and intermolecular interactions (MAE: 0.32 kcal/mol on S66×8). It also enables precise energy minima reproduction and stable molecular dynamics of biological systems. ResFF merges physical constraints with neural expressiveness, offering a robust tool for accurate and efficient molecular simulation.
- 22 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDeep Residual Learning for Molecular Force Fields
Accurate interatomic interaction modeling via force fields is critical for biological studies and drug discovery, but balancing accuracy and generalizability remains challenging. We introduce ResFF (Residual Learning Force Field), a hybrid machine learning force field that employs deep residual learning to integrate physics-based learnable molecular mechanics covalent terms with residual corrections from a lightweight equivariant neural network. Through a three-stage joint optimization, the two components are trained in a complementary manner to achieve optimal performance. Benchmarks show ResFF outperforms classical and neural network force fields in generalization (mean absolute error (MAE): 1.16 kcal/mol on Gen2-Opt, 0.90 kcal/mol on DES370K), torsional profiles (MAE: 0.45/0.48 kcal/mol on TorsionNet-500 and Torison Scan), and intermolecular interactions (MAE: 0.32 kcal/mol on S66×8). It also enables precise energy minima reproduction and stable molecular dynamics of biological systems. ResFF merges physical constraints with neural expressiveness, offering a robust tool for accurate and efficient molecular simulation.
- 13 February 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (6) , 6107-6120
Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods
The p53 Y220C mutation, a prevalent structural variant in human cancers, compromises DNA binding and tumor suppressor functions by destabilizing the protein structure. Leveraging a combined approach of structure-based virtual screening, molecular dynamics simulations, and in vitro assays, we have identified C8, a racemic compound with an indole core and α, β-unsaturated carbonyl groups, as a covalent stabilizer for p53 Y220C. Protein thermal shift and homogeneous time-resolved fluorescence assays confirmed that C8 and its analogs selectively bind to p53 Y220C and restore its DNA binding ability. Subsequent molecular dynamics simulations and structure-activity relationship analyses showed that both enantiomers of C8 form covalent bonds with Cys124 and Cys220, stabilizing the mutant structure. C8 and its analogs emerge as promising lead candidates for restoring the Y220C mutant's transcriptional function, highlights the potential of this scaffold for further optimization into p53 Y220C-targeted therapeutics.
- 13 February 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (6) , 6107-6120
Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods
The p53 Y220C mutation, a prevalent structural variant in human cancers, compromises DNA binding and tumor suppressor functions by destabilizing the protein structure. Leveraging a combined approach of structure-based virtual screening, molecular dynamics simulations, and in vitro assays, we have identified C8, a racemic compound with an indole core and α, β-unsaturated carbonyl groups, as a covalent stabilizer for p53 Y220C. Protein thermal shift and homogeneous time-resolved fluorescence assays confirmed that C8 and its analogs selectively bind to p53 Y220C and restore its DNA binding ability. Subsequent molecular dynamics simulations and structure-activity relationship analyses showed that both enantiomers of C8 form covalent bonds with Cys124 and Cys220, stabilizing the mutant structure. C8 and its analogs emerge as promising lead candidates for restoring the Y220C mutant's transcriptional function, highlights the potential of this scaffold for further optimization into p53 Y220C-targeted therapeutics.